Combined treatment with anti-HER2/neu and anti-4-1BB monoclonal antibodies induces a synergistic antitumor effect but requires dose optimization to maintain immune memory for protection from lethal rechallenge
Open Access
- 6 January 2022
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 71 (4) , 967-978
Abstract
Human epidermal growth factor receptor type 2 (HER2)-positive breast cancer that is treated with anti-HER2/neu monoclonal antibody (mAb) is not free from late recurrences. Addition of anti-4-1BB mAb to anti-HER2/neu mAb has been demonstrated to strengthen the cytotoxic antitumor response. Our study expands on this by revealing the influence of anti-4-1BB mAb addition on the immune memory of anti-HER2/neu mAb. We designed murine breast cancer models by implanting TUBO and TUBO-P2J cell lines in mice, which were then treated with anti-HER2/neu and/or anti-4-1BB mAb. After complete surgical and/or chemical regression of the tumor, the mice were rechallenged with a second injection of cancer cells. Notably, anti-HER2/neu and anti-4-1BB mAb combination therapy had a synergistic antitumor effect at the initial treatment. However, the combination therapy did not evoke immune memory, allowing the tumors to thrive at rechallenge with reduced CD44+ expression in CD8+ T cells. Immune memory was also impaired when anti-4-1BB mAb was administered to naive CD8+ T cells but was sustained when this was administered to activated CD8+ T cells. In an attempt to resist the loss of immune memory, we controlled the dose of anti-4-1BB mAb to optimize the stimulation of activated CD8+ T cells. Immune memory was achieved with the dose regulation of anti-4-1BB mAb to 1 mg/kg in our model. Our study demonstrates the importance in understanding the adaptive immune mechanism of anti-HER2/neu and anti-4-1BB mAb combination therapy and suggests a dose optimization strategy is necessary to ensure development of successful immune memory.Keywords
Funding Information
- Bio & Medical Technology Development Program of the National Research Foundation (NRF) of Korea funded by the Korean government (No.2019M3A9H1103607)
- National Research Foundation of Korea (No.2017R1C1B5076247)
- SAMJINPHARM.CO., LTD (SJ-IIT-17-07)
This publication has 32 references indexed in Scilit:
- Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapyProceedings of the National Academy of Sciences, 2011
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive ImmunityCancer Cell, 2010
- Anti-HER2 vaccines: new prospects for breast cancer therapyCancer Immunology, Immunotherapy, 2010
- A novel interaction between HER2/neu and cyclin E in breast cancerOncogene, 2010
- Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedBlood, 2009
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2008
- Targeting the function of the HER2 oncogene in human cancer therapeuticsOncogene, 2007
- Genes Affecting the Cell Cycle, Growth, Maintenance, and Drug Sensitivity Are Preferentially Regulated by Anti-HER2 Antibody through Phosphatidylinositol 3-Kinase-AKT SignalingJournal of Biological Chemistry, 2005
- Cytokines in cancer pathogenesis and cancer therapyNature Reviews Cancer, 2004
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsNature, 1999